Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

Helmut Gadner, Milen Minkov, Nicole Grois, Ulrike Pötschger, Elfriede Thiem, Maurizio Aricò, Itziar Astigarraga, Jorge Braier, Jean Donadieu, Jan-Inge Henter, Gritta Janka-Schaub, Kenneth L. McClain, Sheila Weitzman, Kevin Windebank, Stephan Ladisch

Blood (2013) 121 (25): 5006–5014.

https://doi.org/10.1182/blood-2012-09-455774

Published: 2013

Journal Articles

Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells

Caroline Hutter, Max Kauer, Ingrid Simonitsch-Klupp, Gunhild Jug, Raphaela Schwentner, Judith Leitner, Peter Bock, Peter Steinberger, Wolfgang Bauer, Nadia Carlesso, Milen Minkov, Helmut Gadner, Georg Stingl, Heinrich Kovar, Ernst Kriehuber

Blood (2012) 120 (26): 5199–5208.

https://doi.org/10.1182/blood-2012-02-410241

Published: 2012

Includes: Supplemental data

Journal Articles

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

Helena Trottestam, AnnaCarin Horne, Maurizio Aricò, R. Maarten Egeler, Alexandra H. Filipovich, Helmut Gadner, Shinsaku Imashuku, Stephan Ladisch, David Webb, Gritta Janka, Jan-Inge Henter, for the Histiocyte Society

Blood (2011) 118 (17): 4577–4584.

https://doi.org/10.1182/blood-2011-06-356261

Published: 2011

Includes: Supplemental data

Journal Articles

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Blood (2011) 118 (8): 2077–2084.

https://doi.org/10.1182/blood-2011-03-338707

Published: 2011

Includes: Supplemental data

Journal Articles

Selective engraftment of donor CD4 + 25 high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation

Markus G. Seidel, Gerhard Fritsch, Thomas Lion, Birgit Jürgens, Andreas Heitger, Rosa Bacchetta, Anita Lawitschka, Christina Peters, Helmut Gadner, Susanne Matthes-Martin

Blood (2009) 113 (22): 5689–5691.

https://doi.org/10.1182/blood-2009-02-206359

Published: 2009

Journal Articles

CD20 up-Regulation in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia during Induction Treatment Translates into Higher Rituximab-Sensitivity.

Andishe Attarbaschi, Angela Schumich, Georg Mann, Oskar A. Haas, Helmut Gadner, Michael Dworzak

Blood (2008) 112 (11): 906.

https://doi.org/10.1182/blood.V112.11.906.906

Published: 2008

Journal Articles

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

Michael N. Dworzak, Angela Schumich, Dieter Printz, Ulrike Pötschger, Zvenyslava Husak, Andishe Attarbaschi, Giuseppe Basso, Giuseppe Gaipa, Richard Ratei, Georg Mann, Helmut Gadner

Blood (2008) 112 (10): 3982–3988.

https://doi.org/10.1182/blood-2008-06-164129

Published: 2008

Journal Articles

Response: Design and reporting of clinical trials in LCH

Stephan Ladisch, Robert McCarter, Ulrike Pötschger, Helmut Gadner

Blood (2008) 112 (8): 3528.

https://doi.org/10.1182/blood-2008-08-167916

Published: 2008

Journal Articles

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Blood (2008) 111 (9): 4477–4489.

https://doi.org/10.1182/blood-2007-09-112920

Published: 2008

Includes: Supplemental data

Journal Articles

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

Helmut Gadner, Nicole Grois, Ulrike Pötschger, Milen Minkov, Maurizio Aricò, Jorge Braier, Valerie Broadbent, Jean Donadieu, Jan-Inge Henter, Robert McCarter, Stephan Ladisch

Blood (2008) 111 (5): 2556–2562.

https://doi.org/10.1182/blood-2007-08-106211

Published: 2008

Includes: Supplemental data

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

Valentino Conter, MD, André Schrauder, MD, Helmut Gadner, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Michael Dvorzak, MD, Andrea Biondi, MD, Claus R. Bartram, PhD, Giuseppe Basso, MD, Martin Stanulla, MD, Maurizio Aricò, MD, Karl Welte, MD, Giuseppe Masera, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 544.

https://doi.org/10.1182/blood.V110.11.544.544

Published: 2007

Journal Articles

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Anja Möricke, MD, Alfred Reiter, MD, Martin Zimmermann, PhD, Helmut Gadner, MD, Martin Stanulla, MD, Wolf-Dieter Ludwig, MD, Jochen Harbott, PhD, Georg Mann, MD, Felix Niggli, MD, Günter Henze, MD, Karl Welte, MD, Thomas Klingebiel, MD, Charlotte Niemeyer, MD, Felix Zintl, MD, Hansjörg Riehm, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 584.

https://doi.org/10.1182/blood.V110.11.584.584

Published: 2007

Journal Articles

Immunogenicity of Childhood T-ALL.

Renate Panzer-Grümayer, Andrea Inthal, Gerd Krapf, Thomas Felzmann, Helmut Gadner, Alexander Dohnal

Blood (2006) 108 (11): 1840.

https://doi.org/10.1182/blood.V108.11.1840.1840

Published: 2006

Journal Articles

BIOV-111 a European Phase II Trial of Clofarabine (Evoltra ® ) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.

Pamela Kearns, MD,PhD, Gerard Michel, MD, Brigitte Nelken, MD, Simon Joel, PhD, Essam Al-Ghazaly, MD, Auke Beishuizen, MD,PhD, Valentino Conter, MD, Helmut Gadner, MD, Gunter Henze, MD, Hazel Smith, PhD, Andre Baruchel, MD, Vaskar Saha, MD, PhD

Blood (2006) 108 (11): 1859.

https://doi.org/10.1182/blood.V108.11.1859.1859

Published: 2006

Journal Articles

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Valentino Conter, Maria Grazia Valsecchi, Daniela Silvestri, Myriam Campbell, Eduardo A. Dibar, Edina Magyarosy, Helmut Gadner, Jan Stary, Yves Benoit, Hansjoerg Riehm, Giuseppe Masera, Martin Schrappe

Blood (2005) 106 (11): 11.

https://doi.org/10.1182/blood.V106.11.11.11

Published: 2005

Journal Articles

Results in Children and Adolescents Treated According to Study AML-BFM 98: Less Toxic Deaths in the Short-Cycle Arm Than in the 6-Week Consolidation Arm.

Ursula Creutzig, MD, Reinhardt Dirk, MD, Joerg Ritter, MD, Norbert Graf, MD, Johannes Herrmann, MD, Thomas Klingebiel, MD, Alfred Reiter, MD, Helmut Gadner, MD, Felix Niggli, MD, Jan Stary, MD, Martin Zimmermann, PhD

Blood (2005) 106 (11): 274.

https://doi.org/10.1182/blood.V106.11.274.274

Published: 2005

Journal Articles

RNAi Silencing of TEL-AML1 Reveals a Heat Shock Protein Dependent Mechanism in the Development of Leukemia.

Christofer Diakos, Christopher Gerner, Andrea Inthal, Helmut Gadner, Renate Panzer-Grümayer

Blood (2005) 106 (11): 2844.

https://doi.org/10.1182/blood.V106.11.2844.2844

Published: 2005

Journal Articles

Treatment Response and Outcome in Childhood t(1;19)/ TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.

Leo Kager, MD, Thomas Lion, MD, PhD, Andishe Attarbaschi, MD, Margit Koenig, PhD, Sabine Strehl, PhD, Oskar A. Haas, MD, Michael N. Dworzak, MD, Martin Schrappe, MD, PhD, Helmut Gadner, MD, Georg Mann, MD

Blood (2005) 106 (11): 1458.

https://doi.org/10.1182/blood.V106.11.1458.1458

Published: 2005

Journal Articles

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95

Wilhelm Woessmann, Kathrin Seidemann, Georg Mann, Martin Zimmermann, Birgit Burkhardt, Ilske Oschlies, Wolf-Dieter Ludwig, Thomas Klingebiel, Norbert Graf, Bernd Gruhn, Heribert Juergens, Felix Niggli, Reza Parwaresch, Helmut Gadner, Hansjoerg Riehm, Martin Schrappe, Alfred Reiter, for the BFM Group

Blood (2005) 105 (3): 948–958.

https://doi.org/10.1182/blood-2004-03-0973

Published: 2005

NARROW

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Selective engraftment of donor CD4 + 25 high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation

CD20 up-Regulation in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia during Induction Treatment Translates into Higher Rituximab-Sensitivity.

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

Response: Design and reporting of clinical trials in LCH

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Immunogenicity of Childhood T-ALL.

BIOV-111 a European Phase II Trial of Clofarabine (Evoltra ® ) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Results in Children and Adolescents Treated According to Study AML-BFM 98: Less Toxic Deaths in the Short-Cycle Arm Than in the 6-Week Consolidation Arm.

RNAi Silencing of TEL-AML1 Reveals a Heat Shock Protein Dependent Mechanism in the Development of Leukemia.

Treatment Response and Outcome in Childhood t(1;19)/ TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only